Research map: Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Back to the article

Papers in this map

  1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2018 · 88286 citations · Cited by this paper
  2. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions · Yan Zhong · 2024 · 109 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment · Douglas Hanahan · 2012 · 4781 citations · Cited by this paper
  5. Single-Cell Transcriptomics for Unlocking Personalized Cancer Immunotherapy: Toward Targeting the Origin of Tumor Development Immunogenicity · Saeed Khodayari · 2023 · 16 citations · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up · John B.A.G. Haanen · 2017 · 2383 citations · Cited by this paper
  8. Stem Cell Therapy in Limb Ischemia: State-of-Art, Perspective, and Possible Impacts of Endometrial-Derived Stem Cells · Saeed Khodayari · 2022 · 14 citations · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer · Jeffrey S. Miller · 2005 · 1932 citations · Cited by this paper
  11. Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment · Tongzheng Chen · 2024 · 12 citations · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor # · Bastian Hoechst · 2009 · 649 citations · Cited by this paper
  14. Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis · Hikmet Can Çubukçu · 2022 · 4 citations · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Interleukin-12: Biological Properties and Clinical Application · Michele Del Vecchio · 2007 · 609 citations · Cited by this paper
  17. Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions · Gohar Shahwar Manzar · 2026 · 4 citations · Cites this paper
  18. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  19. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer · Eleni G. Iliopoulou · 2010 · 279 citations · Cited by this paper
  20. Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies · Qianwen Chen · 2025 · 3 citations · Cites this paper
  21. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  22. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response · Christopher Garris · 2020 · 141 citations · Cited by this paper
  23. PD-1/CTLA-4 antibody AK104 in advanced solid tumors after PD/PD-L1 treatment failure: A retrospective cohort study · Jun Yi · 2025 · 2 citations · Cites this paper
  24. Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · 2026 · Related
  25. Untitled · Cited by this paper
  26. CAR-NK cell therapy for hematological malignancies · Gohar Shahwar Manzar · 2026 · 1 citation · Cites this paper
  27. Untitled · Cited by this paper
  28. CAR design equips diverse immune cells with unique antigen-specific activation identities · Ayano Sugiyama-Finnis · 2026 · Cites this paper
  29. Untitled · Cited by this paper
  30. Investigating the causal relationship between immune cells and colorectal cancer risk using bidirectional and multivariable Mendelian randomization analysis · Jiajie Zhou · 2025 · Cites this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)